Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 34

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 34
---
 to generate revenue via a partner, thereby earning
royalty and/or milestone income; however, this is not expected to materialize in the foreseeable future, and there can be no guarantee
we will be able to find a licensing partner for our product candidates. Even if our product candidates were to successfully achieve regulatory
approval, we do not know when any of the product candidates will generate revenue, if at all. Our ability to generate revenue from our
product candidates also depends on a number of additional factors, including our ability, and the ability of any licensing partners, to:

| • | successfully complete development activities; |

| • | complete and submit new drug applications to the European Medicines Agency, or the EMA, the Medicines                                    
 and Healthcare Products Regulatory Agency in the United Kingdom, or the MHRA, the FDA, and any other foreign regulatory authorities, and 
 obtain regulatory approval for products for which there is a commercial market;                                                          |

| • | set a commercially viable price; |

| • | obtain commercial qualities of the products at acceptable cost levels; |

| • | develop and maintain a commercial organization capable of sales, marketing and distribution in the markets 
 where the product is to be sold; and                                                                       |

| • | obtain adequate reimbursement from third parties, including government, departments and healthcare payors. |

In addition, because of the
numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development
or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or
if we will be able to achieve or maintain profitability. Even if we are able to complete the process described above, we anticipate incurring
significant costs.

Even if we are able to generate
royalty and/or milestone revenues from the sale of product candidates, we may not become profitable and may need to obtain additional
funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we
may be unable to continue our operations at planned levels and may be forced to cease or reduce our operations.

| 18 |

There can be no assurance
that we will operate profitably, produce a reasonable return, if any, on investment, or remain solvent. If our strategy proves unsuccessful,
stockholders could lose all or part of their investment.

If we require or seek to raise additional capital to fund our operations and we fail to obtain necessary financing, we may be unable to complete the development of